| Identification | Back Directory | [Name]
LRRK2-kinase inhibitor | [CAS]
1285515-21-0 | [Synonyms]
CS-1790
GSK2578215
SK2578215A
GSK2578215A
GSK2578125A
GSK2578215A, >=98%
LRRK2-kinase inhibitor
GSK2578215A >=98% (HPLC)
LRRK2 inhibitor GS2578215A
LRRK2 inhibitor GSK2578215A
LRRK2-kinase inhibitor USP/EP/BP
5-(2-Fluoropyridin-4-yl)-2-phenylmethoxy-N-pyridin-3-ylbenzamide
2-(benzyloxy)-5-(2-fluoropyridin-4-yl)-N-(pyridin-3-yl)benzaMide
5-(2-Fluoro-4-pyridinyl)-2-(phenylmethoxy)-N-3-pyridinylbenzamide
BenzaMide, 5-(2-fluoro-4-pyridinyl)-2-(phenylMethoxy)-N-3-pyridinyl-
5-(2-fluoro-4-pyridinyl)-2-[(phenylmethyl)oxy]-N-3-pyridinylbenzamide
5-(2-Fluoro-4-pyridinyl)-2-(phenylmethoxy)-N-3-pyridinylbenzamide GSK2578215A | [Molecular Formula]
C24H18FN3O2 | [MDL Number]
MFCD22665702 | [MOL File]
1285515-21-0.mol | [Molecular Weight]
399.417 |
| Chemical Properties | Back Directory | [Boiling point ]
556.1±50.0 °C(Predicted) | [density ]
1.292±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: soluble15mg/mL, clear | [form ]
powder | [pka]
12.31±0.70(Predicted) | [color ]
white to beige |
| Hazard Information | Back Directory | [Uses]
GSK2578215A is a potent, selective LRRK2 inhibitor and a promising therapeutic for treating Parkinson''s disease. | [Biological Activity]
GSK2578215A is a potent inhibitor of leucine-rich repe at kinase-2 (LRRK2) also known as dardarin or PARK8a kinase with mutations linked to Parkinson′s disease. Because the most common mutationG2019Senhances LRRK2 kinase activityit is hoped th at LRRK2 inhibitors may be useful in treating the disease. GSK2578215A inhibited both wild-type and G2019S mutant LRRK2 kinase activity with IC50s of 10.9 and 8.9 nM respectively. It has good blood-brain barrier (BBB) permeability with a high ratio of brain to plasma distribution in mice.''GSK2578215A stimulates mitochondrial fragmentationautophagy and mitophagy. | [storage]
Store at RT |
|
|